#telaprevir

Hepatitis C knocked pro wrestler Devon “Hannibal” Nicholson out of the ring, but a cure landed him back in the fight.

Staging liver fibrosis among those with hepatitis C virus and only treating advanced cases is not cost-effective compared with treating all.

With interferon quickly becoming a thing of the past, what kind of side effects still remain in the new hepatitis C regimens?

The first study to track in real time the decay of hepatitis C has found that the virus breaks down more quickly in the blood than in the live...

An open letter from People with Bleeding Disorders and HCV urging the U.S. government to stop clinical trials on a potentially damaging hepati...

As hepatitis C treatment undergoes a revolution, the doors are swinging wide open for people coinfected with HIV to be cured of hep C.

A panel of medical experts in California has lambasted Gilead Sciences for its exorbitant pricing its new hepatitis C treatment, Sovaldi (sofo...

Daclatasvir and Sovaldi, given with or without ribavirin, cured between 92 and 100 percent of people with genotypes 1, 2 and 3 of hepatitis C.

“This is a very significant advance.”

A recent liver conference made it more clear than ever that the means to blow hepatitis C off the map is just within reach.

Incivek added to interferon and ribavirin shortens the treatment duration and raises cure rates among gay, HIV-positive men with acute hepatit...

This week I have reached an important Mile Marker with completing triple therapy for Hep C using Incivek (telaprevir), Peg Interferon and Riba...

The FDA has sped up the development and approval process for promising new hepatitis C therapies from three different companies.

There are differences between Incivek (telaprevir) and Victrelis (boceprevir) in treatment for Hepatitis C, specifically side effects and leng...

The FDA has given Janssen Research and Development priority review status for its investigational hepatitis C therapy simeprevir.

Preparing for a great revolution in hepatitis C care, major pharmaceutical companies are in a mad dash toward achieving blockbuster status.